Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Cancer Vaccines01:30

Cancer Vaccines

946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

PIMPC-GNN: Physics-Informed Multiphase Consensus Learning for Enhancing Imbalanced Node Classification in Graph Neural Networks.

IEEE transactions on neural networks and learning systems·2026
Same author

Impact of health system interventions to improve access to external beam radiotherapy: a scoping review.

Frontiers in oncology·2026
Same author

Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.

Nature·2026
Same author

The optical origin of the human skin color 'banana' in CIELAB space.

bioRxiv : the preprint server for biology·2026
Same author

Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.

European urology focus·2026
Same author

Treatment times for rural and urban patients with aneurysmal subarachnoid hemorrhage in a provincial hub-and-spoke network.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026

相关实验视频

Updated: Jan 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

前列腺癌的新辅助疗法-当前模式和未来方向

Kieran Sandhu1,2, Abdullah Al-Khanaty1,3, David Hennes1,4

  • 1Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia.

Cancers
|January 10, 2026
PubMed
概括

高风险前列腺癌的新辅助疗法正在发展. 更新的治疗方法,如雄激素受体通路抑制剂和放射性体疗法,有望改善生存和个性化治疗策略.

关键词:
ADT ADT 在线播放在ARPI中,ARPI是ARPI.新辅助疗法是一种新辅助疗法.前列腺癌是前列腺癌.放射性合物治疗疗法

更多相关视频

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

656
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

相关实验视频

Last Updated: Jan 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

656
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

科学领域:

  • 在瘤学瘤学.
  • 泌尿器科 泌尿器科 泌尿器科 泌尿器科
  • 医学物理 医学物理

背景情况:

  • 高风险和局部晚期前列腺癌的复发率和死亡率很高.
  • 新辅助期在急性前列腺切除或放射治疗之前为系统治疗提供了一个关键的窗口.
  • 之前的新辅助疗法,包括第一代雄激素剥夺疗法 (ADT) 和基于多塞的疗法,显示出有限的生存益处.

研究的目的:

  • 审查目前关于高风险前列腺癌新辅助疗法的证据.
  • 探索新兴的系统性治疗和未来的研究方向在新辅助设置.

主要方法:

  • 这是一个叙述性综述,综合了现有的临床试验数据和研究结果.
  • 专注于评估各种新辅助全身疗法的疗效和结果.
  • 讨论正在进行的III期试验和新的治疗方法.

主要成果:

  • 第二代雄激素受体通路抑制剂 (ARPI) 与ADT结合,在转移性环境中显示出显著的生存益处,并且正在新辅助试验中进行研究.
  • [177Lu]Lu-PSMA-617放射性干疗法在新辅助环境中显示出前景.
  • 放射治疗 (RT) 单独面临着消除微转移性疾病的挑战,类似于手术,引发了对强化新辅助系统治疗的兴趣.

结论:

  • 新辅助性ARPI和放射性连接体疗法代表了对高风险前列腺癌的有希望的进展.
  • 未来的研究将专注于个性化的新辅助剂策略,包括基因组和分子分析.
  • 识别免疫反应的亚型可以指导在术前环境中使用免疫导向疗法.